Breast cancers with immunohistochemistry (IHC) scores of 1+ or 2+ and negative in situ hybridization (ISH) are termed HER2-low according to the 2018 ASCO/CAP guidelines (3, 4). The gene discussed is ERBB2; the disease is breast carcinoma.